Quarterly report pursuant to Section 13 or 15(d)

Schedule of Net Assets Acquired to be Allocated to Goodwill (Details)

v3.21.2
Schedule of Net Assets Acquired to be Allocated to Goodwill (Details) - Akers Biosciences, Inc [Member] - USD ($)
6 Months Ended
Jun. 30, 2021
Apr. 16, 2021
Acquired Indefinite-lived Intangible Assets [Line Items]    
Total Consideration $ 42,477,346  
Cash and Cash Equivalents   $ 1,380,852
Marketable Securities   29,480,524
Other Receivables   3,026,137
Prepaid Expenses   192,314
Investment in Oravax, Inc.   1,500,000
Trade and Other Payables   (3,601,020)
Net Tangible Assets Acquired   31,978,807
Excess of Purchase Price Over Net Assets Acquired to be Allocated to Goodwill   $ 10,498,539